The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection.

OnabotulinumtoxinA Injection: Rates of Urinary Retention in Women with Urgency Incontinence

Urgency urinary incontinence (UUI) is a common condition affecting women, causing an uncontrollable urge to urinate. This study examines the rates of urinary retention in women undergoing initial intravesical injections of onabotulinumtoxinA (BoNTA) for UUI. The researchers retrospectively reviewed the medical records of women who had received an initial injection of BoNTA, focusing on the incidence of both symptomatic and asymptomatic urinary retention, a condition where the bladder is unable to empty completely.

Urinary Retention Following OnabotulinumtoxinA Injection

The study found that urinary retention occurred in 10% of patients who received an initial BoNTA injection, with 8% experiencing symptomatic retention and 2% experiencing asymptomatic retention. The researchers also observed that women who had previously undergone anti-stress urinary incontinence procedures were more likely to experience retention after BoNTA injection.

Understanding the Risks and Benefits of OnabotulinumtoxinA Injection

This study underscores the importance of understanding the potential risks associated with BoNTA injections for UUI, particularly the risk of urinary retention. The findings highlight the need for careful patient selection and close monitoring to minimize the risk of complications. Healthcare providers should discuss the potential risks and benefits of BoNTA injection with patients before treatment to ensure informed decision-making.

Dr. Camel's Conclusion

Just like a camel navigating the vast desert with a keen sense of its surroundings, healthcare providers need to carefully consider the potential risks and benefits of treatment options like BoNTA injections. This study sheds light on the rates of urinary retention following BoNTA injection, emphasizing the importance of individual risk assessment, close monitoring, and open communication with patients to ensure the best possible outcomes. By understanding the intricacies of treatment choices, we can guide patients towards a healthier and more fulfilling life.